FY2025 Earnings Estimate for Pfizer Issued By Zacks Research

Pfizer Inc. (NYSE:PFE) – Stock analysts at Zacks Research lifted their FY2025 earnings per share estimates for Pfizer in a research report issued on Tuesday, November 25th. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings per share of $3.15 for the year, up from their previous estimate of $3.10. The consensus estimate for Pfizer’s current full-year earnings is $2.95 per share. Zacks Research also issued estimates for Pfizer’s Q4 2025 earnings at $0.58 EPS, Q1 2026 earnings at $0.73 EPS, Q2 2026 earnings at $0.61 EPS, Q3 2026 earnings at $0.99 EPS, Q4 2026 earnings at $0.68 EPS and Q3 2027 earnings at $1.00 EPS.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.08. The business had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS.

Several other equities analysts also recently commented on the stock. Scotiabank assumed coverage on shares of Pfizer in a report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price target on the stock. Guggenheim boosted their target price on Pfizer from $33.00 to $35.00 and gave the company a “buy” rating in a research report on Monday. Bank of America upped their target price on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Sanford C. Bernstein reiterated a “market perform” rating and issued a $30.00 price target on shares of Pfizer in a report on Friday, October 31st. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $28.39.

Pfizer Trading Down 0.0%

Shares of PFE opened at $25.72 on Wednesday. The company’s fifty day simple moving average is $24.97 and its 200-day simple moving average is $24.55. The company has a market cap of $146.21 billion, a P/E ratio of 13.68, a P/E/G ratio of 0.81 and a beta of 0.54. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer has a twelve month low of $20.92 and a twelve month high of $27.69.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be issued a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. Pfizer’s payout ratio is presently 100.00%.

Institutional Investors Weigh In On Pfizer

Institutional investors and hedge funds have recently bought and sold shares of the company. Norges Bank bought a new stake in shares of Pfizer in the second quarter valued at about $2,270,157,000. Amundi increased its position in Pfizer by 43.4% during the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock valued at $1,265,277,000 after purchasing an additional 15,758,846 shares during the period. Nuveen LLC bought a new stake in shares of Pfizer in the 1st quarter valued at about $389,861,000. Vanguard Group Inc. lifted its position in shares of Pfizer by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock worth $12,928,730,000 after purchasing an additional 10,198,330 shares during the period. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Pfizer by 51.9% during the first quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company’s stock valued at $670,407,000 after purchasing an additional 9,041,990 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.